Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.

MH, Einstein; P, Takacs; A, Chatterjee; RS, Sperling; N, Chakhtoura; MM, Blatter; J, Lalezari; MP, David; L, Lin; F, Struyf; G, Dubin

doi:10.4161/hv.36121

Public

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial.

Shared by NobleBlocks on Jan 1, 2014 • 12:00 AM UTC

Authors:

Einstein MH

Takacs P

Chatterjee A

Abstract

The observer-blind, randomized, age-stratified, head-to-head study (NCT00423046) comparing immunogenicity and safety of HPV-16/18 and HPV-6/11/16/18 vaccines in healthy women aged 18-45 y was completed. Five y after vaccination, in subjects from the Month 60 according-to-protocol cohort (seronegativ...

Subject

Antibodies

Models

Safety

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!